Lazard Asset Management LLC Has $3.90 Million Stock Holdings in Charles River Laboratories International, Inc. $CRL

Lazard Asset Management LLC grew its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 13.2% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,637 shares of the medical research company’s stock after acquiring an additional 2,644 shares during the period. Lazard Asset Management LLC’s holdings in Charles River Laboratories International were worth $3,905,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Tema Etfs LLC bought a new position in shares of Charles River Laboratories International during the 4th quarter valued at $26,000. Los Angeles Capital Management LLC acquired a new position in Charles River Laboratories International during the fourth quarter worth $42,000. Sfam LLC bought a new position in Charles River Laboratories International during the fourth quarter valued at about $43,000. Activest Wealth Management raised its holdings in Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after buying an additional 218 shares in the last quarter. Finally, Elyxium Wealth LLC acquired a new stake in shares of Charles River Laboratories International in the fourth quarter worth about $46,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Analysts Set New Price Targets

CRL has been the subject of several recent analyst reports. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a research note on Wednesday, July 1st. Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a report on Friday, May 8th. Mizuho upped their target price on Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a research report on Monday, July 13th. JPMorgan Chase & Co. lowered their price target on Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Monday, April 13th. Finally, Citigroup reissued a “buy” rating on shares of Charles River Laboratories International in a research report on Wednesday, July 8th. Eleven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Charles River Laboratories International currently has an average rating of “Moderate Buy” and a consensus target price of $220.75.

Insider Buying and Selling

In other Charles River Laboratories International news, Director James C. Foster sold 75,000 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the transaction, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. The trade was a 70.36% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Down 0.9%

CRL stock opened at $232.49 on Friday. The stock has a market capitalization of $11.20 billion, a price-to-earnings ratio of -61.83, a price-to-earnings-growth ratio of 2.61 and a beta of 1.40. The company has a 50-day moving average of $206.60 and a two-hundred day moving average of $188.14. Charles River Laboratories International, Inc. has a 52-week low of $144.26 and a 52-week high of $242.73. The company has a debt-to-equity ratio of 0.90, a current ratio of 1.36 and a quick ratio of 1.03.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 EPS for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. Charles River Laboratories International had a positive return on equity of 15.36% and a negative net margin of 4.59%.The business had revenue of $995.83 million for the quarter, compared to analyst estimates of $977.46 million. During the same period in the previous year, the company posted $2.34 earnings per share. The firm’s revenue for the quarter was up 1.2% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities research analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.